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Abstract
Background: The Hygiene Hypothesis proposes that infection exposure protects against inflammatory conditions.
Helminths possess allergen-like molecules and may specifically modulate allergy-related immunological pathways to
inhibit responses which protect against them. Mass drug administration is recommended for helminth-endemic
communities to control helminth-induced pathology, but may also result in increased rates of inflammation-mediated
diseases in resource-poor settings. Immunological studies integrated with implementation of helminth control
measures may elucidate how helminth elimination contributes to ongoing epidemics of inflammatory diseases.
We present the design of the Lake Victoria Island Intervention Study on Worms and Allergy-related diseases (LaVIISWA),
a cluster-randomised trial evaluating the risks and benefits of intensive versus standard anthelminthic treatment for
allergy-related diseases and other health outcomes.
Methods/Design: The setting is comprised of island fishing communities in Mukono district, Uganda. Twenty-six
communities have been randomised in a 1:1 ratio to receive standard or intensive anthelminthic intervention for
a three-year period. Baseline characteristics were collected immediately prior to intervention rollout, commenced
in February 2013. Primary outcomes are reported wheeze in the past 12 months and atopy (skin prick test response
and allergen-specific immunoglobulin (asIg) E concentration). Secondary outcomes are visible flexural dermatitis,
helminth infections, haemoglobin, growth parameters, hepatosplenomegaly, and responses to vaccine antigens. The trial
provides a platform for in-depth analysis of clinical and immunological consequences of the contrasting interventions.
Discussion: The baseline survey has been completed successfully in a challenging environment. Baseline characteristics
were balanced between trial arms. Prevalence of Schistosoma mansoni, hookworm, Strongyloides stercoralis and Trichuris
trichiura was 52%, 23%, 13%, and 12%, respectively; 31% of Schistosoma mansoni infections were heavy (>400 eggs/
gram). The prevalence of reported wheeze and positive skin prick test to any allergen was 5% and 20%, respectively.
Respectively, 77% and 87% of participants had Dermatophagoides- and German cockroach-specific IgE above 0.35 kUA/
L. These characteristics suggest that the LaVIISWA study will provide an excellent framework for investigating beneficial
and detrimental effects of worms and their treatment, and the mechanisms of such effects.
Trial registration: This trial was registered with Current Controlled Trials (identifier: ISRCTN47196031) on 7
September 2012.
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Background
Allergy-related conditions represent a huge global health
burden [1-4], with the majority of asthma and eczema
cases associated with atopy (elevated allergen-specific
immunoglobulin (Ig) E or skin prick test (SPT) re-
sponses to allergens). Prevalence of these conditions in-
creased dramatically in affluent and middle-income
countries during the 20th century [5-7], with asthma
now affecting about 300 million people [3], and eczema
affecting 5 to 20% of children [2]. Asthma mortality de-
pends on both prevalence and quality of care [6,8]: cur-
rently, asthma prevalence is increasing more rapidly and
asthma severity is greater in low- and middle-income
countries [9]. As the low-income countries of sub-
Saharan Africa enter the epidemiological transition, they
are ill-equipped to encounter such an epidemic.
Globally, around one billion people may be infected
with helminths [10], which cause many subtle and some
severe morbidities [10,11]. Major initiatives for mass
anthelminthic treatment have commenced in the last
decade, with some success [12]. However, the Hygiene
Hypothesis proposes that exposure to infection protects
against inflammatory conditions, including allergy-
related diseases. If this is correct, effective de-worming
will bring risks as well as benefits.
Untreated, helminth parasites survive for decades in
their mammalian hosts and, to do so, must evade or
modulate the host immune response. Evidence from ani-
mal models, and from in vitro studies on human sam-
ples, suggests that helminths can modulate the immune
response not only to themselves, but also to unrelated
pathogens, antigens, immunogens, and allergens [13,14].
Helminth infections may increase susceptibility to micro-
bial pathogens and reduce vaccine efficacy [15]. Helminths
may have particular effects relating to allergic inflam-
mation because they contain a range of molecules hom-
ologous to known allergens, but absent from mammals,
or markedly different from mammalian homologues.
These induce IgE responses in mammalian hosts, and
there is strong evidence that this pathway is involved in
protective immunity against helminths [16]. Modulation
of this atopic pathway is therefore likely to be particularly
important for helminth survival, while concomitantly pro-
tecting against allergic disease [17].
In cross-sectional studies, consistent inverse associa-
tions have been observed between helminths and atopy,
and between hookworm and asthma [18]. Possible expla-
nations are either that helminths protect against asthma
and atopy, or that people genetically predisposed to
asthma and atopy are resistant to helminths, with the
latter hypothesis supported by reports that certain geno-
types are associated with both risk of atopy and resist-
ance to helminths [19,20]. Intervention studies are thus
key to elucidating the relationship between helminths
and allergy, but results are conflicting. Initial studies in
Venezuela [21], Gabon [22], and Vietnam [23] suggested
that atopy, as assessed by SPT positivity, increased fol-
lowing regular anthelminthic treatment. However, a
large cluster-randomised trial among schools in rural
Ecuador showed no effect of two-monthly albendazole for
one year on SPT responses [24]. One possible explanation
for these different findings is differing prevalent helminth
species. No major trial has yet investigated the effects of
treatment of schistosomiasis on asthma, eczema, and
atopy, although schistosomiasis has shown a strong in-
verse association with atopy in observational studies [25].
Apart from effects on allergy, interventions against hel-
minths, particularly schistosomiasis, may have important
benefits for anaemia, growth, hepatosplenic morbidity,
vaccine responses, and cognitive development [11,12,26],
but the community-level effectiveness of mass anthel-
minthic treatment for some of these outcomes [27,28] is
not known.
As mass drug administration is increasingly advocated
and implemented, there is a window of opportunity to
investigate whether, and how, helminths protect against
allergy-related diseases in an epidemiological setting that
no longer exists in high-income countries, and to assess
the risks and benefits of mass anthelminthic treatment.
The Lake Victoria Island Intervention Study on Worms
and Allergy-related diseases (LaVIISWA; Current Con-
trolled Trials identifier: ISRCTN47196031) was designed
to address these questions. We summarise the LaVIISWA
study protocol, describe baseline characteristics of the
study population, and discuss experiences from initiation
of the trial.
Methods/Design
Study setting
The LaVIISWA study is being conducted in the Lake
Victoria islands of Koome sub-county in Mukono dis-
trict, Uganda, which has an approximate population of
16,000 people (Figure 1). The area is remote, being ac-
cessible in two to three hours from Entebbe by motor
powered canoe. The national programme of regular mass
anthelminthic treatment is hampered by the cost of reach-
ing these communities, and by inadequate drug supply.
The island communities consist of well-defined, geo-
graphically separated villages, each governed by a single
administrative committee, and mainly located on the
islands’ shores (Figure 2). For this study, fishing villages
only (not inland villages) are included. There are 27 fish-
ing villages in Koome sub-county (Figure 3) and all are
taking part in the study.
Study design
The LaVIISWA study is an open cluster-randomised trial
of intensive versus standard anthelminthic treatment.
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Randomisation at the individual or household level
would lead to treatment effects being diluted by re-
infection from untreated neighbours, whereas inter-
ventions provided to the whole village are expected to
result in a reduction in transmission within the whole
village.
Fishing villages are the units of randomisation. One of
the villages was randomly selected as a pilot village in
order to optimise procedures, with the remaining 26 vil-
lages participating in the full trial. Clusters receive either
intensive or standard anthelminthic treatment over a
three-year period. A baseline household survey was con-
ducted immediately prior to the first treatment round;
outcomes will be assessed at the end of the three years
using a second household survey.
A small number of the villages comprise more than
one cluster of households and many comprise a cluster
of households located directly on the lake shore and
scattered inland households. In such villages, all house-
holds receive the allocated intervention, but the sam-
pling frame for the two household surveys only includes
households in the main cluster of households. This ‘fried
egg’ design creates buffer zones between clusters, re-
duces risk of contamination, and minimises variability in
cluster characteristics.
Information and consent
This project is being conducted in collaboration with the
Vector Control Division (VCD) at the Uganda Ministry
of Health. Prior to the start of the trial, the proposed
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Figure 1 Location of the study area.
Figure 2 Aerial photograph of the study setting (courtesy of Professor
Russell Stothard).
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protocol was presented to, and consultations held with,
district leaders. Consultations were also held with health
service providers on the islands, and collaborations were
established to facilitate the work and coordinate with
outreach activities to remote communities. Village health
teams (VHTs) are working with the research team during
surveys and for drug distribution activities. Meetings were
held in each of the villages to explain the work and answer
questions. The local council committees in each village
were asked for written permission for the trial to be con-
ducted there.
Written individual consent for participation in the
intervention was not sought since this is a community-
based intervention and the minimum provision meets
the standard recommended by the VCD. Although indi-
viduals are encouraged to participate in the intervention
programme allocated to their village, they may refuse
treatment at any time, and this was made clear at the
meetings and continues to be emphasised during treat-
ment distribution. Individual written informed consent
(for adults aged ≥18 years and emancipated minors,
and for children by a parent or guardian) and assent
(for children aged 8 to 17 years) are sought for survey
participation.
Interventions
The standard intervention (as recommended by the
VCD) comprises home-delivered single-dose albenda-
zole (400 mg) given twice-yearly to all community
members aged ≥1 year, and annual praziquantel treat-
ment (approximately 40 mg/kg, estimated by height
pole) to all individuals measuring ≥94 cm (the standard
height pole range) [29]. This height range excludes
many pre-school children [30]. Individuals who are sick
are excluded.
The intensive intervention comprises home-delivered
triple-dose albendazole and single-dose praziquantel,
both given quarter-yearly to all community members
aged one year or older. For praziquantel administration
to young children, the extended height pole (≥60 cm) is
used, with tablets crushed and given in juice [31] be-
cause a paediatric formulation for praziquantel is not yet
available. For albendazole, a three-day course of 400 mg
daily is given, in order to provide more effective treat-
ment for Trichuris trichiura [32,33]. The first dose is
directly observed, and the subsequent two doses pro-
vided. Pregnant women are given only single-dose alben-
dazole; this is considered acceptable in pregnancy by the
World Health Organization (WHO) [34], but multiple
doses might lead to accumulation of higher drug levels,
with possible adverse consequences [34-36].
The intervention is not blinded. Treatments for both
arms of the trial are provided by the research programme,
supervised by research team members in collaboration
with the VCD, and distributed by VHTs. The VHT distrib-
utors document uptake against household registers, re-
cording individual participation or refusal of treatment
and adverse effects.
Figure 3 Study villages (clusters), Koome sub-county, Mukono district, Uganda. Villages receiving standard intervention indicated in white, villages
receiving intensive intervention indicated in red, pilot village indicated in yellow, location of the main health centre (HC) indicated as a black triangle.
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Randomisation
A public randomisation ceremony was conducted at a
school near the sub-county headquarters on 15 August
2012, attended by representatives from each community
and sub-county leaders. The randomisation ceremony had
three stages. In stage one, a pilot village (to receive standard
intervention) was randomly selected, from a shortlist of
eight villages categorised as suitable for piloting activities
on the basis of size and accessibility, by a community mem-
ber who drew a numbered ball from an opaque bag. In
stage two, restricted randomisation was then used to allo-
cate the remaining 26 villages in a 1:1 ratio to the trial arms,
while ensuring balance on village size, distance to Koome
health centre (the main health centre on the islands), and
previous helminth treatment coverage. Village size was
approximated by the number of households, estimated
using information from local council leaders. Villages were
grouped into four categories (>1,000 households, 600 to
1,000 households, 300 to 599 households, or <300 house-
holds). Distances from each village centre to Koome health
centre were calculated from GPS coordinates. Previous hel-
minth treatment coverage was defined as the estimated
number of people treated with praziquantel (based on
national programme records) divided by the estimated
village population. The following restrictions were applied:
1. Village size: number of villages within each size
category must not differ between the two arms by
more than one.
2. Distance to Koome health centre: difference between
the two arms in mean distance must be less than
0.25 km.
3. Previous helminth treatment coverage: the difference
between the two arms in mean coverage (estimated
proportion treated) must be lower than 0.01.
For each of the 8 possible pilot villages, a random
sample of 1,000 possible allocations of the remaining 26
villages to the two trial arms, satisfying the restrictions,
was pre-prepared by the study statistician. Possible allo-
cations, with 13 villages assigned to group 0 and 13 vil-
lages assigned to group 1, were numbered from 000 to
999. In stage two, three balls that together gave a num-
ber between 000 and 999 were randomly selected by
community members, and the corresponding allocation
from the list was used to assign each village to group 0
or group 1. Finally, in stage three, a ball was selected at
random by the sub-county chairman to determine which
group (1 or 0) would receive the intensive and which
would receive the standard intervention.
Baseline and three-year household surveys
A baseline survey was conducted in each cluster imme-
diately prior to the first treatment round, allowing us to
assess the comparability of villages between the two
arms and the trial analysis to be adjusted for any base-
line imbalances; this information could not be used for
the restricted randomisation, since for logistical reasons
it was necessary to initiate the intervention in each clus-
ter immediately after the baseline survey. Outcome mea-
sures will be assessed in a similarly designed household
survey conducted three years after the intervention be-
gins, before the final round of anthelminthic treatment
is delivered to all villages.
Available listings of households in each village were
checked and updated by the research team and VHTs to
provide the sampling frame for the baseline survey, and
will be further updated to provide the sampling frame
for the three-year survey. For the baseline survey, a simple
random sample of 45 households, expected to comprise
125 individuals, was selected from each of the study clus-
ters. In selected and participating households, all house-
hold members (defined as people who sleep in the same
house and share meals), of all ages, were eligible for inclu-
sion in the survey.
Outcomes
Primary outcomes for the trial, assessed at the three-
year survey, are:
1. wheeze within the last 12 months (only in participants
aged ≥5 years);
2. atopy: SPT positivity (only in participants aged ≥1
year); and
3. atopy: allergen-specific (as)IgE concentration (only
in participants aged ≥1 year).
Secondary outcomes are:
1. visible flexural dermatitis (all participants);
2. helminth infections (all participants);
3. haemoglobin (only in participants aged ≥1 year);
4. growth as measured by height-for-age and weight-
for-age z-scores (only in participants aged ≤19 years);
5. hepatosplenomegaly (all participants); and
6. vaccine responses (participants aged ≥1 year).
Outcome measurement
Survey procedures used for baseline and planned for the
three-year survey are identical. A questionnaire is com-
pleted regarding household features, and individual ques-
tionnaires are completed for each household member.
Questions elicit social, demographic, and family character-
istics, and information regarding asthma, eczema, and al-
lergy symptoms. To ensure comparability with studies
conducted elsewhere, we employ questions from the
International Study on Allergy and Asthma in Children
(ISAAC) questionnaire, with supplementary questions
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from the UK diagnostic criteria for atopic eczema
[37,38]. The co-primary outcome, wheeze within the
last 12 months, is assessed through this questionnaire.
Our pilot work suggested imperfect understanding of
wheeze in this community, so the ISAAC video ques-
tionnaire for asthma, kindly provided by Dr Julian Crane
(University of Otago, New Zealand), is also administered.
Lung function parameters are also assessed using a
hand-held spirometer (Micro 1 Diagnostic Spirometer,
CareFusion, Chatham Marine, UK). This instrument has
internal controls which categorise efforts as a good blow
or an inadequate blow. Each participant is trained to use
the spirometer, and the best result of three good blows
(taken ≥20 seconds apart) is recorded (forced expiratory
volume in one second (FEV1), forced vital capacity
(FVC), and peak expiratory flow (PEF)).
A general history and examination, including height
and weight, and a check for hepatosplenomegaly, is
done. All individuals are examined for visible flexural
dermatitis; all team members are trained in the standar-
dised approach described by Williams [39]. SPTs are
performed on all participants aged one year and older,
using standard methods, with three allergens (Dermato-
phagoides mix, Blomia tropicalis, and German cock-
roach (Blattella germanica)) and positive and negative
controls (ALK-Abelló, supplied by Laboratory Special-
ities (Pty) Ltd, Randburg, South Africa). Total IgE and
asIgE (specific to allergens such as Dermatophagoides
and German cockroach) are measured using enzyme-
linked immunosorbent assay (ELISA) [35] (Additional
file 1); concentrations are measured in ng/mL. Binary
variables for an atopic response for each allergen are
created by converting results to kUa/L using the Immu-
noCAP conversion factor of 2.42 ng/mL to 1 kUa/L [40],
and applying the European Academy of Allergy and
Clinical Immunology (EAACI) recommended cut-off of
0.35 kUA/L.
Each participant is asked for one stool sample, from
which two slides are examined (by different individuals)
using the Kato-Katz method [41]. The remaining sample is
suspended in ethanol and stored at −80°C to allow further
investigation for Necator americanus and Strongyloides
stercoralis, and, for a subset of 200 participants in the
baseline survey, Schistosoma mansoni and Ancylostoma
duodenale, using real-time polymerase chain reaction
(PCR) [42,43] (Additional file 1). In addition, urine is col-
lected for assessment of circulating cathodic antigen
(CCA) of S. mansoni (Rapid Medical Diagnostics, Pretoria,
South Africa).
Blood samples of 14 mL are obtained from individ-
uals aged ≥13 years, 10 mL from children aged 5 to 12
years, and 6 mL from children aged 1 to 4 years; no blood
sample is obtained from infants. Blood samples are used
for haematology, haemo-parasitology, and immunological
assays. Haemoglobin is assessed by HemoCue® (HemoCue
AB, Angelholm, Sweden); Mansonella perstans infection is
determined by a modified Knott’s method [44]. Malaria
is assessed by thick blood film. Adults are offered HIV
counselling and testing in collaboration with health ser-
vice providers.
To assess vaccine responses, assays are conducted for
levels of antibody to vaccine antigen. Anti-tetanus and
anti-measles antibody levels are measured by ELISA
[45]. Cellular responses to tetanus toxoid and mycobac-
terial antigens are also measured using a whole blood
assay, as previously described and used in our studies
[46]. For comparison, responses to relevant allergens
and schistosome antigens are also measured.
In a sample archive, peripheral blood mononuclear
cells are separated and stored in liquid nitrogen. Serum,
plasma, and a whole cell pellet suitable for DNA extrac-
tion are also stored. Participants’ consent provides for
use of samples in future studies, subject to approval by
the relevant ethical committees. Depending upon the
epidemiological results obtained, these samples should
allow us to investigate pathways of the immune response
to allergens that are modified during helminth infection,
using a range of techniques.
Sample size
For the three-year survey we aim to sample 125 individ-
uals per cluster. Based on preliminary data collected be-
fore the trial, prevalence of each primary outcome was
estimated to be 10%. Table 1 indicates the power that
the trial will have to detect risk ratios (RR) of 1.4 to 1.6
for intensive versus standard anthelminthic treatment at
a 5% significance level, assuming a coefficient of vari-
ation of 0.2 [47]. If the coefficient of variation is higher,
Table 1 Power to detect differences between the two intervention arms at a significance level of 5%, assuming a
coefficient of variation of 0.2
Outcome Sample size
per arm
Prevalence in standard
intervention arm
Risk ratio for intervention effect
1.4 1.5 1.6
Wheeze within last 12 months in participants ≥5-years-old 1,300 10% 67% 83% 92%
Atopy: positive skin prick test in participants ≥1-year-old 1,560 10% 72% 87% 95%
Atopy: allergen-specific immunoglobulin E concentration >0.35 kUA/L in
participants ≥1-year-old
1,560 10% 72% 87% 95%
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at 0.25, then the trial will have approximately 80% power
to detect risk ratios of 1.5 or higher.
Analysis plan
Analysis will be done by intention-to-treat, that is, par-
ticipants will be analysed in the clusters in which they
are resident at the three-year survey, regardless of
whether they have received the intervention or not. We
will employ statistical methods that allow for within-
cluster correlations. Primary analysis will be done at the
cluster-level since this is most robust when the number
of clusters is relatively small [48].
For binary outcomes, cluster-specific proportions will
be calculated, and the arithmetic mean of these within
each intervention arm will be used as a summary meas-
ure of the proportion experiencing the outcome in that
arm. Crude risk ratios will be calculated directly from
these summary measures. P values for the effect of the
intervention will be calculated using t-tests comparing
cluster-level proportions between the treatment arms,
and 95% confidence intervals for risk ratios will be de-
rived using a Taylor series approximation approach to
estimate standard error. It is possible that cluster-
specific proportions will be positively skewed. If this is
the case, log transformations will be applied and the
analysis approach will be modified accordingly [48].
Analysis of quantitative outcomes will follow a similar
approach, with the effect of the intervention quantified
as the difference in mean outcome between the two
arms, and a 95% confidence interval for this calculated
directly using the t-distribution and standard formulae
for the standard error of the difference between two
means.
Adjusted analyses for the effect of the intervention will
also be conducted. For each outcome, the cluster-
specific prevalence (or mean for quantitative outcome)
of the outcome as assessed at the baseline survey will be
adjusted for, a priori, to improve the precision of inter-
vention effect estimates. We will also investigate adjust-
ment for prognostic factors that showed imbalance
between treatment arms in the baseline survey, despite
randomisation. Adjustment will be performed using a
two-stage approach [48].
Ethical considerations
Ethical approval has been granted from the Research
and Ethics Committee of the Uganda Virus Research In-
stitute (reference: GC127), the Uganda National Council
for Science and Technology (reference: HS 1183), and
the London School of Hygiene and Tropical Medicine
(reference: 6187).
Study participants suffer the inconvenience and minor
discomfort entailed by the study procedures, in particu-
lar the blood draws and SPTs. The research team are
experienced in all these procedures, which are regularly
undertaken within epidemiological and clinical studies of
asthma, eczema, and atopy. SPTs are carried out by an
experienced nurse and, although not painful, could be
viewed as invasive; we therefore obtain a separate con-
sent signature for this procedure.
Participants are provided with a soft drink or snack
when procedures have been completed. No financial
compensation is provided, since participants are not re-
quired to travel or incur costs. However, the communi-
ties benefit from anthelminthic drug provision, and
individuals who are considered likely to have asthma or
eczema are advised on the management of the condition.
Moreover, research visits offer opportunities for Koome
Health Centre staff to conduct outreach visits at which
general health care and immunisations can be provided
(health centres often lack funds to provide transport for
these activities).
As schistosomiasis can cause significant direct morbid-
ity [11] all villages receive at least the standard interven-
tion. A potential concern is that standard intervention
communities may be disadvantaged compared to the in-
tensive intervention communities. However, because the
VCD has been unable to reach some island communities
regularly, the research programme is likely to result in
better coverage throughout the study area than in the
past.
Mass treatment with anthelminthics is a well-established
public health practice and important adverse and serious
adverse events are not expected. Higher rates of adverse
events and serious adverse events are expected in the
intensive arm because these villages are treated more
often, and information is requested more often. This will
be taken into account, for example, by reporting rates per
treatment round.
Discussion
Mass anthelminthic treatment has been widely advo-
cated as a means of improving general health outcomes,
but its benefits are not conclusively proven for these
outcomes, and there is some evidence that worm re-
moval may lead to an increase in allergy-related disease
outcomes [35]. The LaVIISWA study aims to address
the relative risks and benefits of mass anthelminthic
treatment and to provide a platform for immunological
investigation of effects observed. To effectively address
the first of these objectives, randomisation was done at
the village level. This cluster-randomisation approach
guards against dilution of the effects of anthelminthic
treatment by re-infection from untreated neighbours, is
expected to result in a reduction in transmission within
the whole village, and replicates programmatic ap-
proaches. The LaVIISWA study is the first cluster-
randomised trial to investigate the effects of anthelminthic
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treatment on allergy-related outcomes in an area where S.
mansoni is the dominant helminth species, and is also the
first to examine the effect of treating the whole commu-
nity. The three-year follow-up period is longer than has
been used in other trials examining similar questions
[18], thus longer-term effects of worm removal should
be captured.
Experiences from conducting the trial
During initial visits community members welcomed the
trial, and leaders from all villages attended the randomisa-
tion ceremony and gave written consent for their village’s
participation. Logistical challenges identified included the
requirement for a suitable boat (a motorised transport
canoe, or ‘kinara’, built locally) and suitable accommoda-
tion: lodges were identified in two villages, and a wooden
dormitory built in a third, with the support of the local
council, generating three bases from which all villages can
be reached fairly comfortably within a day. Planning and
equipping of a mobile field clinic and lab was also re-
quired. The team spends a week in the field at a time.
Cold storage for reagents and plasma and serum samples
is managed using ice boxes, with ice brought from the
mainland, and topped up in the islands if necessary (ice is
brought in regularly from the mainland to service the fish-
ing industry).
Between October 2012 and July 2013, the study research
team conducted the pre-intervention baseline survey
and, together with VHTs, delivered the first round of
the intervention. Although an up-to-date household
listing was used as a sampling frame for the survey,
houses were frequently found to be temporarily or per-
manently empty, and the average number of occupants
per household was lower than expected. Of the 1,170
households (45 per cluster) selected for the baseline
survey, 88% agreed to take part, and 2,316 (95%) of the
2,427 residents of these households were included in
the survey. Of these, 92% gave a blood sample, 86%
provided a stool sample, and 93% of those aged at least
one year underwent SPT.
The concepts of wheeze and eczema are not well
understood in the study setting. There is no direct trans-
lation of the word wheeze in the vernacular, Luganda,
which is the lingua franca in the islands. The question,
‘Has your child had wheezing or whistling in the chest
in the past 12 months?’ from the ISAAC questionnaire is
rendered, ‘Omwana wo yali afunyeko akakaaba mu
kifuba mu bbanga lya myezi 12 egiyise?’ which literally
means, ‘Has your child had a crying sound in the chest
in the past 12 months?’. To aid understanding, all partic-
ipants were shown the video questionnaire for wheeze.
Agreement between reported wheeze in the last 12
months and responding yes to any question in the video
questionnaire was fairly low (κ = 0.38), although stronger
when restricted to participants under five-years-old (κ =
0.66). Reassuringly, participants reporting wheeze had,
on average, reduced FEV1 and PEF results (mean FEV1:
98.1% and 104.3% of the predicted value for age and sex
for those with and without wheeze, respectively, t-test
P = 0.03; mean PEF: 88.3% and 99.2% for those with
and without wheeze, respectively, t-test P <0.001).
The team encountered logistical challenges in examin-
ing Kato-Katz slides within the 30 to 60 minutes neces-
sary for reliable detection of hookworm species, and S.
stercoralis cannot be detected by the Kato-Katz method.
Therefore, stored stool samples from all participants
were investigated for N. americanus and S. stercoralis
using faecal PCR. For a subgroup of 200 participants,
samples were also investigated using faecal PCR for S.
mansoni and A. duodenale . PCR results for S. mansoni
showed good agreement with Kato-Katz results, and no
A. duodenale infections were detected. Thus further in-
vestigation of remaining participants for these species
using PCR was not done.
Baseline characteristics of the trial population
Baseline data were available from 2,316 residents of
1,026 households. Table 2 summarises baseline charac-
teristics of villages and households, and Table 3 summa-
rises characteristics of individuals, overall and by trial
arm. The environment is rather uniform: accommoda-
tion generally comprises single-storey buildings of rudi-
mentary wooden construction (95%), with a mixture of
thatched and plastic sheeting roofs (90%), and beaten
earth floors (99%). Sanitation is limited, with only a
quarter of villages having any public toilets, and fewer
than 10% of households having access to a private toilet.
Only a third of villages have a water source other than
the lake, with a large majority of households (75%)
obtaining water for drinking and other purposes entirely
from the lake. A total of 42% of the households owned
animals, with chickens and pigs being the most com-
mon, and nearly all of these frequently entered the
house. The population has a varied tribal background,
however, with over 30 tribes reported, representing all
regions of Uganda, as well as neighbouring countries in
East and central Africa, only 35% are Baganda (the dom-
inant tribe on the mainland in this district). Of the
adults, 53% are fishermen or involved in work related to
the fishing industry, 15% are involved in farming or lum-
bering, 8% are housewives, while others provide services
such as shops, food, and entertainment. The age distri-
bution of cluster residents is bimodal, with low numbers
of children aged five to eighteen years, because children
are sent to school on the mainland. Among adults, the
sex distribution is weighted towards men.
Baseline findings indicate a very heavy burden of dis-
ease in the study population. Adult HIV prevalence was
Nampijja et al. Trials  (2015) 16:187 Page 8 of 14
18%, over twice the national figure of 7.2% [49], al-
though asymptomatic malaria was relatively uncommon
(6%). Helminth prevalence was very high despite the ef-
forts of the national programme to provide annual treat-
ment: 52% were infected with S. mansoni, approximately
a third of whom were classified as having heavy infec-
tions based on WHO cut-offs [50]. Urine assay and faecal
PCR detection of S. mansoni were done on two different
subgroups of the study participants; urine assay classified
72% of individuals as infected (compared to 48% classi-
fied as infected by Kato-Katz in this subgroup), while
PCR classified 56% as infected (compared to a Kato-
Katz figure of 47% in the PCR-tested subgroup).
Prevalence of hookworm (using PCR), S. stercoralis
(using PCR), T. trichiura (using Kato-Katz), and A.
lumbricoides (using Kato-Katz) were 23%, 13% 12%,
and 1%, respectively, with an overall figure of 31% in-
fected with an albendazole-susceptible helminth spe-
cies. Figure 4 shows the prevalence of the most
common helminth infections by age group. S. mansoni
was highly prevalent in all but the youngest age group.
The prevalence of T. trichiura peaked in school-aged
children. Hookworm prevalence increased to a peak in
the 15 to 19 year age group and then gradually de-
clined, while prevalence of S. stercoralis increased
steadily with age.
Table 2 Comparison of village and household-level characteristics, between trial arms
Characteristics1 Standard anthelminthic treatment Intensive anthelminthic treatment
Village characteristics (n = 13) (n = 13)
Households per village, median (IQR) 180 (114 to 290) 265 (98 to 296)
Villages with an alternative water source to the lake 23% 38%
Villages with at least one public toilet 46% 8%
Villages where some households have privately owned toilets 69% 92%
Household characteristics (n = 524) (n = 502)
Crowding
≤1 person/room 50% 44%
1-2 people/room 26% 32%
>2 people/room 24% 25%
Own animal(s) 41% 43%
Asset score, mean (SD)2 2.7 (1.6) 2.6 (1.6)
Wall materials
Wood 98% 92%
Mud and wattle 2% 8%
Other 1% 0%
Roof materials
Plastic sheets and thatch 69% 75%
Thatch 16% 17%
Iron sheets 13% 7%
Plastic sheets 2% 1%
Floor materials
Beaten earth 49% 50%
Covered beaten earth 49% 49%
Other 2% 1%
Indoor cooking with wood/charcoal/paraffin 55% 63%
Household has toilet 7% 9%
Household takes drinking water from lake 81% 69%
Household takes washing water from lake 93% 91%
Household had no mosquito control measures 50% 48%
1Missing values in standard and intensive arms, respectively: crowding: 0, 1; animal ownership: 0, 1; asset score: 0, 1; house construction materials: 0, 1; indoor
cooking: 0, 1; household toilet: 0, 1; household drinking water: 1, 1; household washing water: 0, 1; and household mosquito control: 0, 1. 2Asset score is number
of items owned out of car, boat, motorbike, bicycle, television, radio, mobile phone, and bed. IQR, Interquartile range.
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Table 3 Comparison of individual-level characteristics, between trial arms
Characteristics1 Standard anthelminthic treatment
(n = 1,159)
Intensive anthelminthic treatment
(n = 1,157)
Socio-demographic characteristics
Age in years, median (IQR) 24 (8 to 33) 24 (7 to 32)
Sex, % male 56% 53%
Occupation type (adults only)
No personal income 11% 10%
Unskilled, no income 16% 22%
Some skill or capital required, low income 59% 46%
Education, skills or capital required, low to moderate income 5% 9%
Facility owner (such as a shop, boat, or restaurant) 8% 11%
Maternal tribe
Central 29% 36%
Western 16% 12%
Eastern 19% 23%
Northern 17% 14%
Non-Ugandan 18% 14%
Paternal tribe
Central 33% 40%
Western 15% 12%
Eastern 20% 21%
Northern 18% 14%
Non-Ugandan 13% 12%
Number of older siblings, mean (SD) 2.8 (2.8) 2.9 (3.1)
Number of younger siblings, mean (SD) 2.6 (2.7) 2.6 (2.7)
Any previous worm treatment in last 12 months 44% 39%
Treatment with albendazole in last 12 months 29% 27%
Treatment with praziquantel in last 12 months 20% 14%
Infections
Schistosoma mansoni (Kato-Katz) 56% 49%
Schistosoma mansoni (urine CCA) 72% 73%
Schistosoma mansoni intensity (Kato-Katz)
Uninfected 44% 51%
Low 22% 21%
Moderate 15% 13%
Heavy 18% 14%
Hookworm (Necator americanus; PCR) 23% 23%
Strongyloides stercoralis (PCR) 13% 13%
Trichuris trichiura (Kato-Katz) 12% 11%
Ascaris lumbricoides (Kato-Katz) 2% 1%
Mansonella perstans 3% 2%
Plasmodium falciparum 6% 7%
HIV (adults only) 17% 19%
1Missing values in standard and intensive arms respectively: age: 4, 1; sex: 6, 7; occupation: 8, 7; maternal tribe: 18, 17; paternal tribe: 15, 17; older siblings: 6, 7;
younger siblings: 7, 9; any worm treatment: 17, 15; albendazole treatment: 28, 32; praziquantel treatment: 30, 31; Kato-Katz results: 172, 148; PCR results: 172, 150;
urine results: 642, 757; M. perstans: 115, 102; P. falciparum: 107, 94; HIV: 65, 60. CCA, circulating cathodic antigen; IQR, interquartile range; PCR, polymerase
chain reaction.
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The results from the three different techniques for
assessing S. mansoni infection status illustrate the fact
that prevalence estimates based on Kato-Katz analysis
of a single stool sample, an approach known to lack
sensitivity [51], are likely to be underestimates. For the
post-intervention outcome survey, we will conduct
urine assays for all participants, and do PCR for S. ster-
coralis and hookworm. Combining these techniques
will give good sensitivity for each helminth in the final
survey.
Data on allergy-related primary and secondary out-
comes at baseline is shown in Table 4. Reported wheeze
in the last 12 months was rare (<5%), although the
proportion reporting wheeze in response to the video
questionnaire was higher, at 10%. Visible flexural eczema
was very rare. A total of 20% of participants were atopic
as assessed by SPT, with German cockroach being the
most common allergen. The median (IQR) asIgE was 72
(8.5 to 199.5) ng/mL for Dermatophagoides and 11 (3.5
to 32.5) ng/mL for German cockroach, and 77% of par-
ticipants had a Dermatophagoides IgE response higher
than the EAACI cut-off of 0.35 kUa/L, with 87% above
the cut-off for German cockroach.
Although some variables appeared a little unbalanced
in the village-level comparison (where the denominator
for each trial arm is 13), comparisons at household and
0
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1
0-4 5-9 10-14 15-19 20-24 25-29 30-34 35-39 40-44 45+
Age (years)
S. mansoni Hookworm
S. stercoralis T. trichiura
Figure 4 Prevalence of Schistosoma. mansoni, hookworm, Strongyloides stercoralis, and Trichuris trichiura infections, by age. S. mansoni and T. trichiura
determined by Kato-Katz, N. americanus, and S. stercoralis determined by PCR.
Table 4 Comparison of outcomes ascertained at the baseline survey, between trial arms
Outcomes1 Standard anthelminthic treatment
(n = 1,159)
Intensive anthelminthic treatment
(n = 1,157)
Wheeze in last 12 months 5% 4%
Video questionnaire wheeze in last 12 months 9% 10%
Atopy (skin prick test)
Any 21% 20%
Dermatophagoides 10% 10%
Blomia 10% 10%
German cockroach 14% 13%
Atopy (allergen-specific immunoglobulin E > 0.35 kUa/L)
Dermatophagoides 76% 78%
German cockroach 86% 89%
Visible flexural dermatitis 1% 1%
1Missing values in standard and intensive arms respectively: wheeze: 7, 8; video questionnaire: 123, 18; atopy (SPT): 165, 175; atopy (asIgE): 107, 92; visible flexural
dermatitis: 100, 71.
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individual level suggest that good balance has been
achieved between trial arms.
Potential limitations
For ethical reasons, villages in the standard arm will re-
ceive the VCD-recommended schedule of anthelminthic
treatment, thus we will not be able to investigate the ef-
fects of worm removal with respect to an untreated popu-
lation. However, the standard treatment is not expected to
be as effective as the intensive treatment in worm removal
due to the very high baseline prevalence and intensity,
poor sanitation, and very limited access to water from
sources other than the lake, all of which make the chances
of re-infection considerable. Interim surveys of helminth
prevalence will be conducted annually in each study clus-
ter, to assess the effectiveness of each trial intervention.
The efficiency of a cluster-randomised trial with fixed
total sample size is maximised with a large number of
clusters of small sample size. The LaVIISWA study in-
cludes a relatively small number of clusters, due to both
logistic and budgetary constraints. Nevertheless, the trial
has good power to detect moderate to large effects of
the intervention. A possible consequence of having a rela-
tively small number of clusters was imbalance between
trial arms, but baseline data indicate that the restricted
randomisation approach was successful in achieving
balance on important covariates. These data will also
allow us to conduct adjusted analyses allowing for baseline
variations in outcome prevalence between individual study
clusters (which may exist even though overall balance
between trial arms has been achieved), thus minimising
residual variability in the analysis. We have presented
baseline data summary statistics unadjusted for the survey
design (which is not self-weighting); however, figures
allowing for this are very similar.
The diagnosis of asthma within epidemiological stud-
ies is challenging because the condition is, by definition,
variable and individuals may be asymptomatic at the
time of assessment. Comparisons between approaches
have been made, with the conclusion that standardised
questionnaires about wheeze have the greatest validity
for population surveys, particularly when supplemented
with a video questionnaire [52,53]. For this reason we
decided to use reported wheeze as the primary outcome
to reflect asthma prevalence in this study. The use of
pictures and videos has aided understanding of the condi-
tions being studied and the associations between reported
wheeze, video questionnaire responses, and spirometry
provides some reassurance.
Conclusions
Despite logistical challenges, the study team have suc-
cessfully conducted a large baseline survey, and the
interventions have now successfully been rolled out to
all clusters. Apart from providing baseline data, conduct-
ing the baseline survey has provided information that
will be essential in refining the approach to be used for
the three-year post-intervention survey. It is possible
that short-term interventions (such as the three-year
duration of this trial) may have limited effects. However,
the study design is such as to allow for longer-term
follow-up, and repeat surveys at a greater time-interval,
if our results suggest that this is likely to be of interest.
Trial status
The cluster-level intervention was rolled out from October
2012 and will conclude in July 2016. Recruitment into
the final survey where the effect of the cluster-level
intervention will be assessed will begin in October 2015
and is expected to conclude in July 2016.
Additional file
Additional file 1: Detailed laboratory methods for measurement of
allergen-specific Immunoglobulin (Ig) E ELISA, and for helminth DNA
extraction and real-time polymerase chain reaction (PCR).
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